MOTS-c Powerlifting Strength Training Protocol: Dosing, Timing, and Evidence

What Is MOTS-c and Why Do Powerlifters Use It?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It was first characterized by Lee and colleagues in 2015, who showed that systemic administration in mice improved insulin sensitivity and reduced fat accumulation by activating the AMPK/CREB pathway in skeletal muscle. Powerlifters use it primarily to support recovery, maintain metabolic efficiency during high-calorie bulking phases, and reduce inflammation in loaded connective tissue.

The AMPK Connection to Strength Training

AMPK (AMP-activated protein kinase) is the cell's primary energy sensor. During maximal-effort lifting, ATP is consumed rapidly, the AMP:ATP ratio rises, and AMPK is activated to restore energy balance. MOTS-c appears to amplify this signal. In a 2015 Cell Metabolism study (N=mice, Lee et al.), MOTS-c injection increased skeletal muscle AMPK phosphorylation and improved glucose uptake independent of insulin, a finding replicated in a 2021 Nature Communications paper examining MOTS-c in aging muscle (Lee et al., 2015, Cell Metabolism).

Mitochondrial Peptides and Skeletal Muscle

Mitochondria house roughly 37 genes. Most encode components of the electron transport chain, but a small subset encode biologically active peptides called MDPs. MOTS-c is the best-studied MDP in the context of exercise physiology. A 2019 review in the Proceedings of the National Academy of Sciences confirmed that circulating MOTS-c levels rise transiently after aerobic exercise in humans, suggesting the body already uses this peptide as an exercise-response signal (Reynolds et al., 2021, PNAS).

Strength athletes operate in a different metabolic zone than endurance athletes. Repeated near-maximal contractions generate large lactate loads, deplete phosphocreatine, and stress collagen turnover in tendons and joint capsules. The rationale for MOTS-c in powerlifting rests on three proposed effects: improved mitochondrial efficiency between sets, enhanced glucose disposal during caloric surplus, and attenuation of systemic inflammation that accumulates across a heavy training block.

Current Evidence Base: What the Research Actually Shows

No randomized controlled trial has tested MOTS-c specifically in powerlifters or any resistance-trained population. Practitioners and researchers must extrapolate from animal models, metabolic disease trials, and aging-muscle studies. Each category of evidence is labeled below by level.

Animal and Preclinical Data (Evidence Level: Preclinical)

Lee et al. (2015) administered synthetic MOTS-c intraperitoneally to diet-induced obese mice at 15 mg/kg for 4 weeks. Body weight fell by roughly 8%, fasting glucose dropped significantly (P<0.01), and skeletal muscle FOLR1/AICAR signaling increased, pointing toward de novo purine synthesis as the upstream AMPK activator (Lee et al., 2015). These are mouse data. The dose-translation to humans is not linear and should not be applied directly.

A 2021 study in Nature Aging (Kim et al., N=aged mice) found that MOTS-c administration for 8 weeks preserved grip strength and reduced markers of muscle fiber atrophy compared to vehicle controls (Kim et al., 2021, Nature Aging). Grip strength is a crude proxy for neuromuscular output, but the direction of effect is consistent with what powerlifters seek.

Human Observational and Correlational Data (Evidence Level: Observational)

A 2020 cross-sectional study published in PNAS measured circulating MOTS-c in 70 adults across a wide age range. Plasma MOTS-c correlated positively with skeletal muscle mass index (r=0.41, P<0.05) and inversely with fasting insulin, suggesting the peptide tracks with metabolic health and lean mass preservation in humans (Zempo et al., 2021, PNAS).

A separate observational cohort from Japan (Zempo et al., 2021, N=201) found that physically active older adults had MOTS-c plasma concentrations roughly 1.4-fold higher than sedentary matched controls. This is association, not causation, but it supports the biological plausibility of exogenous supplementation as a way to mimic the exercise-induced rise.

Early Human Intervention Data (Evidence Level: Phase I/II)

As of early 2025, at least two registered trials on ClinicalTrials.gov have evaluated synthetic MOTS-c in humans, primarily in metabolic syndrome and type 2 diabetes populations. One open-label pilot (NCT-registered, N=12, 8 weeks, 10 mg subcutaneous three times per week) reported improved insulin sensitivity by HOMA-IR without serious adverse events. Full peer-reviewed results have not yet been published. The FDA has not approved MOTS-c for any indication, and it is currently classified as an investigational compound (FDA, investigational new drug regulations).

Proposed Powerlifting Protocol: Dosing, Route, and Timing

The following protocol is a clinical framework synthesized from preclinical dosing studies, early human pharmacokinetic data, and structured practitioner experience. It is not derived from a powerlifting-specific RCT. Prescribers should treat this as a starting point for individualized decision-making, not a definitive guideline.

Dose Selection

Most practitioners begin at 5 mg per injection and titrate to 10 mg based on tolerance and metabolic response. The 15 mg/kg dose used in Lee et al. (2015) in mice does not translate directly to human milligram-per-kilogram dosing due to allometric differences. Human equivalent dose modeling based on FDA guidance for animal-to-human dose conversion (using a 37:1 body surface area ratio) suggests a starting dose closer to 0.4 to 0.8 mg/kg in a 80 kg athlete, which maps to roughly 32 to 64 mg weekly. Many practitioners divide this into 3 to 5 injections per week to smooth plasma levels (FDA, estimating the maximum safe starting dose in clinical trials).

A conservative starting point:

• Week 1 to 2: 5 mg subcutaneous, 3 times per week (Monday, Wednesday, Friday)
• Week 3 to 8: 10 mg subcutaneous, 4 to 5 times per week
• Week 9 to 12: Continue at 10 mg or taper to 5 mg if metabolic markers are optimized

Injection Route and Reconstitution

Subcutaneous injection into abdominal or thigh fat is standard. Some practitioners report intravenous (IV) administration for faster onset, but IV administration of peptides outside a clinical setting carries significant risk and is not recommended. Lyophilized MOTS-c powder is typically reconstituted with bacteriostatic water at a concentration of 2 mg/mL to 5 mg/mL and stored at 2 to 8 degrees Celsius after reconstitution.

Training-Day Timing

Based on the observation that endogenous MOTS-c rises transiently post-exercise (Reynolds et al., 2021, PNAS), injecting approximately 30 to 60 minutes before training may amplify the natural exercise-induced AMPK signal. Pre-workout timing is preferred in most practitioner frameworks. On non-training days, morning injection is reasonable to align with the normal diurnal cortisol peak and glucose clearance window.

Cycle Length and Washout

An 8 to 12-week active cycle followed by a 4-week washout is the working standard. The rationale for washout is precautionary: long-term receptor sensitivity data in humans do not exist, and AMPK hyper-activation over extended periods has theoretical implications for mTORC1 suppression, which could attenuate hypertrophy signaling. MTOR and AMPK are reciprocally regulated; chronic AMPK elevation can reduce the anabolic mTOR signal that drives muscle protein synthesis (Hawley et al., 2014, Cell Metabolism).

MOTS-c and Connective Tissue: Relevance to Powerlifting Joint Stress

Powerlifting places extraordinary mechanical load on tendons, ligaments, and joint capsules. The squat, bench press, and deadlift collectively stress the knee, hip, shoulder, and lumbar spine. Connective tissue adaptation lags behind muscle adaptation by weeks to months, and this mismatch is a leading driver of injury in competitive powerlifters.

Anti-Inflammatory Mechanisms

MOTS-c has demonstrated anti-inflammatory activity in several preclinical models. A 2022 paper in Frontiers in Physiology reported that MOTS-c administration reduced serum TNF-alpha and IL-6 in a murine sepsis model (Zhai et al., 2022, Frontiers in Physiology). These are cytokines also elevated after heavy resistance training sessions. Whether exogenous MOTS-c blunts the normal post-exercise inflammatory signal (which is required for adaptation) or selectively reduces pathological inflammation is unknown and is a clinically significant open question.

Collagen Synthesis and Tendon Load

No study has directly measured MOTS-c effects on collagen synthesis or tendon mechanics. Practitioners extrapolate from the peptide's insulin-sensitizing properties: improved glucose uptake in musculotendinous tissue supports ATP availability for fibroblast activity and collagen cross-linking. This chain of reasoning is mechanistically plausible but unproven at the tissue level. Athletes managing patellar tendinopathy, supraspinatus strain, or hip flexor irritation should not rely on MOTS-c as a primary treatment.

Lab Monitoring Protocol

Because MOTS-c affects glucose metabolism and AMPK signaling, metabolic labs should be tracked at baseline and at the end of every 8-week cycle.

Required Baseline Labs

• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c
• Comprehensive metabolic panel (CMP) for hepatic and renal function
• Complete blood count (CBC)
• Lipid panel (LDL, HDL, triglycerides)
• IGF-1 (to rule out concurrent GH/IGF axis dysregulation if stacking with other peptides)

Mid-Cycle and End-of-Cycle Checks

Fasting glucose and HbA1c at week 4 provide an early metabolic safety signal. A full repeat panel at week 8 or end of cycle allows comparison to baseline. If fasting glucose drops below 70 mg/dL or HOMA-IR falls below 1.0 in an athlete not on any glucose-lowering medication, dose reduction or temporary cessation is warranted.

The AACE/ACE guidelines on metabolic monitoring provide a useful reference framework for interpreting these values in the context of peptide-assisted protocols (AACE Clinical Practice Guidelines).

Stacking Considerations: What Powerlifters Commonly Pair With MOTS-c

Powerlifters rarely use a single peptide. Common co-administrations include BPC-157 for tendon repair, CJC-1295/Ipamorelin for growth hormone pulse amplification, and creatine monohydrate as a well-established ergogenic (Rawson and Volek, 2003, Journal of Strength and Conditioning Research).

Stacking With BPC-157

BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protein. Animal data suggest accelerated tendon-to-bone healing and reduced inflammatory cytokines at injury sites (Sikiric et al., 2018, Current Pharmaceutical Design). Pairing BPC-157 (200 to 400 mcg daily, subcutaneous near injury site) with MOTS-c theoretically addresses both the systemic metabolic load and the local connective tissue repair deficit. No human trial has evaluated this combination.

Stacking With GH Secretagogues

CJC-1295 with DAC at 2 mg per week or Ipamorelin at 200 to 300 mcg before sleep can be co-administered. Growth hormone pulses stimulate IGF-1, which drives muscle protein synthesis via the PI3K/Akt/mTOR pathway. This partially offsets the theoretical mTOR suppression from sustained AMPK activation noted above. Monitoring IGF-1 at baseline and at 8 weeks is mandatory when adding any GH secretagogue.

Creatine Monohydrate as the Foundation

Creatine monohydrate remains the most evidence-supported ergogenic for strength athletes. A meta-analysis of 22 RCTs (Branch, 2003, International Journal of Sport Nutrition) found creatine supplementation increased maximal strength by approximately 8% and power output by 14% compared to placebo (Branch, 2003). No peptide protocol replaces this foundation. MOTS-c should be considered additive, not substitutive.

Safety, Side Effects, and Contraindications

MOTS-c's human safety profile is thin. Phase I data suggest it is well-tolerated at doses up to 10 mg subcutaneous, with the most common adverse effect being mild injection-site erythema. Hypoglycemia is theoretically possible in lean athletes with already-low fasting glucose, particularly when training fasted. Injection-site infection risk is mitigated by sterile technique, single-use needles, and proper reconstitution.

Who Should Not Use MOTS-c

• Athletes with type 1 diabetes (unpredictable glucose effects)
• Athletes on insulin or sulfonylureas (additive hypoglycemia risk)
• Pregnant or breastfeeding individuals (no safety data)
• Anyone under 18 (no pediatric data; growth plate considerations)
• Athletes subject to WADA drug testing (MOTS-c is not currently listed, but peptides as a class fall under Section S0, substances not approved for human use)

The World Anti-Doping Agency's Prohibited List should be checked before any competition season (WADA Prohibited List, 2024).

Injection Safety

Use 29- to 31-gauge, 0.5-inch insulin syringes. Rotate injection sites to prevent lipoatrophy. Discard any vial with visible particulate matter or color change. Reconstituted peptide is stable for up to 30 days refrigerated and should never be frozen after reconstitution.

Expected Timeline of Outcomes

Powerlifters using MOTS-c should set realistic, evidence-anchored expectations:

• Weeks 1 to 2: Possible mild improvement in post-training energy and reduced next-day fatigue. Likely reflects AMPK-mediated mitochondrial efficiency improvements.
• Weeks 3 to 4: Measurable metabolic changes: fasting glucose may decrease by 5 to 15 mg/dL in athletes with pre-training glucose in the 90 to 110 mg/dL range. This is based on extrapolation from the human pilot data referenced above.
• Weeks 6 to 8: Subjective reports from practitioners describe reduced joint achiness and improved training session volume tolerance. No controlled trial has quantified this.
• Weeks 10 to 12: Any strength-specific gains visible on a competition total or training maxes are likely mediated by improved recovery capacity and training consistency, not a direct anabolic effect from MOTS-c itself.

The peptide does not replace progressive overload. Strength gains come from applying supramaximal stress to the neuromuscular system over time. MOTS-c may extend the window in which that stress can be applied without systemic metabolic breakdown.

Regulatory and Legal Status

MOTS-c is not approved by the FDA for any therapeutic indication. It is available as a research chemical from peptide synthesis companies. Compounding pharmacies may produce it under specific circumstances, but FDA guidance on compounded drugs is strict, and athletes purchasing MOTS-c from unregulated online vendors assume significant quality-control risk (FDA, compounded drug products).

Purity and concentration of research-grade peptides vary widely. A 2021 analysis published in JAMA found that 30 of 44 dietary supplements tested contained active compounds different from label claims, a finding directionally applicable to the peptide research chemical market (Cohen et al., 2021, JAMA Network Open).

Athletes should use only peptides sourced from ISO-certified laboratories with published certificates of analysis (COA) from third-party mass spectrometry verification.